论文部分内容阅读
目的探讨人脑胶质瘤中耐药相关基因蛋白LRP、GST-π和MGMT的表达,为临床制定个体化化疗方案提供依据。方法采用免疫组织化学二步法检测53例人脑胶质瘤标本及6例正常脑组织中LRP、GST-π和MGMT的蛋白表达。结果正常组织中三个基因的蛋白表达均为阴性。在人脑胶质瘤标本中,LRP、GST-π和MGMT的蛋白表达阳性率分别是43.4%、43.4%和50.9%;LRP和GST-π的蛋白表达与肿瘤的病理分级呈正相关。结论LRP、GST-π和MGMT在人脑胶质瘤中均有较高表达,检测多种耐药相关基因的蛋白表达,对合理选择胶质瘤化疗药物及预后判断有一定意义。
Objective To investigate the expression of multidrug resistance-related protein LRP, GST-π and MGMT in human glioma and to provide evidence for the development of personalized chemotherapeutic regimens. Methods Immunohistochemistry was used to detect the protein expression of LRP, GST-π and MGMT in 53 human glioma specimens and 6 normal brain tissues. Results The protein expression of three genes in normal tissues was negative. The positive rates of LRP, GST-π and MGMT in human glioma specimens were 43.4%, 43.4% and 50.9%, respectively. The protein expression of LRP and GST-π was positively correlated with the pathological grade of tumor. Conclusions LRP, GST-π and MGMT are highly expressed in human gliomas. Detection of protein expression of multiple drug resistance-related genes may have some significance in the rational selection of glioma chemotherapeutics and prognosis.